Hims & Hers Health Inc. shares declined overnight following FDA safety warnings. Agency scientists questioned the efficacy and safety of seven popular peptides. Staff cited insufficient evidence and limited human data to support compounding these substances.
The announcement creates uncertainty for a regulatory opportunity closely monitored by investors. Needham analyst Ryan MacDonald called the FDA stance surprising but not conclusive. MacDonald suggests a potential path for approval still exists despite the cautious report.
The stock had previously recorded significant gains throughout June. The market reaction reflects immediate uncertainty as the regulatory dialogue continues.